T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback